What this trial studies
The aim of this study is to examine the impact of a concurrent training exercise intervention on menopausal symptoms and key physical and mental health outcomes. The proposed study is powered based on a primary outcome of examining the change in menopausal symptoms using the MenQoL questionnaire. Participants (n=70) will be randomised to an intervention or control group. The intervention group will participate in a 12 week online (via zoom) concurrent training programme, consisting of three forty-five minute sessions (on non-consecutive days) per week that align with WHO exercise recommendations for adults and the control group will maintain their regular activity.
Conditions in scope
- Menopause Symptoms
Interventions
- Concurrent training (Behavioral) — Concurrent training programme
Who can join
Women only · Ages 40 Years to 60 Years
Inclusion criteria
- Women experiencing perimenopause (irregular menstrual cycles of ≥7-day difference in cycle length of consecutive menstrual cycles) and early postmenopause (\< 5 years post menopause).
- Able to safely engage in a concurrent training interventions that combine both aerobic and resistance training.
- Must have reliable internet access and a device capable of participating in online training on zoom.
- Willingness and ability to provide informed consent and comply with study procedures.
- Aged between 40 and 60 years
Exclusion criteria
- BMI \>35 and \<18.5.
- Currently taking psychotropic medication
- Has undergone a hysterectomy
- Current substance abuse
- Current diagnosis of a mental health disorder
- Current diagnosis of a chronic illness
- Currently participating in other structured exercise programmes.
- Recent surgery or hospitalisation in the past 6 months.
Eligibility wording paraphrased from the public record. View the full criteria on ClinicalTrials.gov before contacting a site.
Where it’s happening
| City | State / Region | Facility | Site status |
|---|---|---|---|
| Dublin | Dublin | University College Dublin | Recruiting |
Status & timeline
- Overall status: Recruiting
- Study type: Interventional
- Phase: N/A
- Start date: 2025-12-12
- Primary completion: 2027-12-01
- Last update posted: 2026-02-18
- First posted: 2026-02-18
Sponsor & contact
Lead sponsor: University College Dublin (Other)
For trial site contact information, use the official record at ClinicalTrials.gov. Contact details change frequently and the public record is the source of truth.
Outcome measures
Primary outcomes
- Menopause Symptoms (Menopause-Specific Quality of Life Questionnaire) (Baseline testing (within 2 weeks prior to intervention start date) and post testing (within 2 weeks post intervention end date))
29 symptoms of menopause are listed. For each symptom participants are asked to indicate whether they have experienced the symptom in the past month. If they have experienced it they will be asked to rate (on a scale of 0-6) how much they have been bothered by that symptom (0=not bothered at all; 6=extremely bothered).
Related ClearedRx care
If you’re reading this trial because you have menopause symptoms now, you don’t have to wait for a trial to access evidence-based care. ClearedRx prescribes the same FDA-approved and compounded HRT products that have been studied in trials like this one for decades.
Important. Information from ClinicalTrials.gov as of May 8, 2026. Trial details (status, sites, contacts, eligibility, outcomes) change frequently — always check the official record at https://clinicaltrials.gov/study/NCT07417228 before contacting a site.
ClearedRx is not affiliated with this trial or its sponsor. We index public-domain ClinicalTrials.gov records to help patients find evidence-based context for menopause care decisions. ClearedRx itself is a telehealth menopause/HRT brand — we do not enroll patients in trials.